Regulus Therapeutics (RGLS) Tops Q4 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
• MotorK names Roy Toren to board as Helen Protopapas resigns